You are here

Article Text

Article menu
Download PDFPDF
Letters
PostScript
Postnatal glucocorticoids in preterm neonates: use in French neonatal centres in 2006
  1. E Autret-Leca1,2,
  2. S Bauer3,
  3. C Alberti4,
  4. A P Jonville-Béra1,
  5. Y Aujard5,
  6. L Bensouda-Grimaldi1,2,
  7. O Baud5
  1. 1
    CHRU de Tours, Hôpital Bretonneau, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance et d’Information sur le médicament, Tours, France
  2. 2
    Université François Rabelais Tours, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance et d’Information sur le médicament, Tours, France
  3. 3
    CHRU de Tours, Hôpital Bretonneau, Service de Pharmacologie Clinique, Centre Régional de Pharmacovigilance et d’Information sur le médicament, Tours, France
  4. 4
    Assistance Publique – Hôpitaux de Paris, Hôpital Robert Debré, Unité d’Epidémiologie Clinique, Paris, France
  5. 5
    Assistance Publique – Hôpitaux de Paris, Hôpital Robert Debré, Service de Réanimation et Pédiatrie Néonatales, Paris, France
  1. Professor E Autret-Leca, Service de Pharmacologie—CHRU de Tours—2 boulevard Tonnellé, 37044 Tours cedex 9, France; autret-leca{at}med.univ-tours.fr

https://doi.org/10.1136/adc.2008.141085

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In 1999, 80% of French neonatal centres used corticosteroids, mainly betamethasone, to prevent or to treat bronchopulmonary dysplasia (BPD).1 As many data suggested a low benefit/risk ratio, an updated assessment of this use was necessary.2–5

    Methods

    Questionnaires addressing the use of and indications for corticosteroids were sent to all French neonatal centres.

    Results

    The study was performed over five months (July–November 2006). Questionnaires were sent to 202 centres, of which 186 (92%) centres completed them. Of these 186 centres, 147 (79%) units had a standard protocol for corticosteroids use, …

    View Full Text

    Footnotes

    • Funding: This study was funded by the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSaPS).

    • Competing interests: None.